Top stories in endocrinology: New oral diabetes drug demonstrates positive trial results; HbA1c, BP affect diabetic kidney disease progression

Among the top stories in endocrinology last week were results from a phase 3 trial that found the experimental oral diabetes drug imeglimin achieved its primary safety and efficacy endpoints and a study that found higher HbA1c and blood pressure levels increase risk for diabetic kidney disease in those with type 1 diabetes.

Other highlights included an analysis that suggested unilateral adrenalectomy to treat primary aldosteronism can lead to both transient and persistent adrenal insufficiency, a study that found specific amino acids influenced prediabetes risk and a study that determined greater antidepressant use lowered mortality risk for adults with diabetes plus depression.

Positive phase 3 trial results for potential first-in-class oral diabetes drug

Top-line results from the TIMES 3 study demonstrate the experimental oral diabetes drug imeglimin achieved its primary safety and efficacy endpoints, according to a press release from Poxel and Sumitomo Dainippon Pharma Co. Read more.

HbA1c, BP may affect diabetic kidney disease progression

Among adults with type 1 diabetes, those with higher HbA1c and blood pressure levels may be more likely to develop diabetic kidney disease, according to findings published in the Journal of Diabetes and its Complications. Read more.

Persistent adrenal insufficiency may follow adrenalectomy to treat primary aldosteronism

Unilateral adrenalectomy to treat primary aldosteronism can lead to both transient and persistent adrenal insufficiency, and clinicians should perform postoperative adrenocorticotropic hormone stimulation testing to avoid potential adrenal crisis in patients, according to an analysis of registry data. Read more.

Specific amino acids influence prediabetes risk

Baseline levels of certain amino acids can significantly predict the risk of developing prediabetes 5.5 years later in both black and white adults with a family history of type 2 diabetes, according to findings published in Metabolism. Read more.

Greater antidepressant use lowers mortality risk for adults with diabetes plus depression

An analysis of Korean health insurance data suggests that adults with diabetes and comorbid depression were less likely to die over nearly 9 years of follow-up when prescribed an antidepressant, with both dose-specific and class-specific effects observed, according to findings published in The Journal of Clinical Endocrinology & Metabolism. Read more.